Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 1, 2024
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
Sun, March 31, 2024
[ Sun, Mar 31st 2024
] - WOPRAI
Colin Bristow Maintained (ABOS) at Strong Buy with Decreased Target to $14 on, Mar 31st, 2024
Colin Bristow of UBS, Maintained "Acumen Pharmaceuticals, Inc." (ABOS) at Strong Buy with Decreased Target from $15 to $14 on, Mar 31st, 2024.
Colin has made no other calls on ABOS in the last 4 months.
There are 2 other peers that have a rating on ABOS. Out of the 2 peers that are also analyzing ABOS, 0 agree with Colin's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Colin
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $15 on, Wednesday, March 27th, 2024
- Neena Bitritto-Garg of "Deutsche Bank" Initiated at Strong Buy and Held Target at $8 on, Tuesday, December 12th, 2023
